Browsing: PR Newswire

ATLANTA, Jan. 27, 2025 /PRNewswire/ — Cambium Oncology is pleased to share that their lead drug candidate, ANT308, recently demonstrated outstanding single-agent efficacy and safety in preclinical studies. The drug is mutation-agnostic, and the company observes no toxicity-limiting dosages. In

ABU DHABI, UAE, Jan. 16, 2025 /PRNewswire/ — From 14-16 January, AIKO, a global-leading new energy technology company, made the first appearance with its high-efficiency N-type ABC series products at the 17th World Future Energy Summit (WFES).